Treatment with rapamycin can persistently inhibit mTORC1 signaling, and the combined inhibition of mTORC1 and MNK could totally abrogate the growth of CTCL cells [18]. This evidence concerns the gene ATP7A and primary cutaneous T-cell non-Hodgkin lymphoma.